Disease relevance of Economics, Pharmaceutical

• (Crit Care Med 2000; 28:854-866) KEY WORDS: sedation; anxiolysis; critical care; midazolam; lorazepam; propofol; benzodiazepines; intensive care unit; pharmacoeconomics; critical illness[1]
• An economic analysis of the oral antifungal drugs griseofulvin (GRI), ketoconazole (KET), and terbinafine (TER), currently registered and used in treating onychomycosis of fingernails and toenails, was performed using a model that incorporates elements of both meta-analysis and pharmacoeconomics [2].
• Neutropenia and neoplasia: an overview of the pharmacoeconomics of sargramostim in cancer therapy [3].
• The pharmacoeconomics of the low molecular weight heparin (LMWH) enoxaparin in the prophylaxis and treatment of venous thromboembolism have mostly been investigated in cost-effectiveness studies that estimated direct costs associated with treatment, using decision analyses and clinical outcome data from randomised controlled trials [4].

High impact information on Economics, Pharmaceutical

• This paper discusses the pharmacoeconomics issues relating to the use of the newer therapies for rheumatoid arthritis (RA), namely the tumour necrosis factor (TNF) inhibitors [5].
• Important factors helping to judge the impact of erythropoietin in cancer treatment include pharmacoeconomics and better predictive factors [6].
• Research continues into the efficacy, safety, and pharmacoeconomics of ibandronate [7].
• The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions [8].
• Patient data from that study were analysed to compare the pharmacoeconomics of liposomal versus conventional amphotericin B therapy [9].

Biological context of Economics, Pharmaceutical

• The effect of the diltiazem-cyclosporine interaction on cyclosporine pharmacokinetics, pharmacodynamics, and pharmacoeconomics was studied in 10 recipients of renal allografts [10].

Associations of Economics, Pharmaceutical with chemical compounds

• Further profiles of granisetron (Kytril): effect on quality of life and pharmacoeconomics [11].
• Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure [12].
• A retrospective assessment of safety, efficacy, and pharmacoeconomics of generic azathioprine in heart-transplant recipients [13].
• Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics [14].
• Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections [15].

Gene context of Economics, Pharmaceutical

• The pharmacoeconomics of peri-operative beta-blocker therapy [16].
• Use of pharmacoeconomics in prescribing research. Part 4: is cost-utility analysis a useful tool [17]?
• Overview of the lenograstim pharmacoeconomics programme [18].
• The burden and pharmacoeconomics of epilepsy in India [19].
• The literature is sparse on the pharmacoeconomics of medication non-compliance in patients taking statin medications [20].

Analytical, diagnostic and therapeutic context of Economics, Pharmaceutical

• Data are included from clinical trials evaluating the safety, tolerability, efficacy, and pharmacoeconomics of mifepristone combined with misoprostol for early pregnancy termination [21].

References